BOCA RATON, Fla., May 12 /PRNewswire-FirstCall/ -- Nabi
Biopharmaceuticals (Nasdaq: NABI) today announced that its stockholders
elected the Company's eight Board of Director nominees at its Annual
Meeting of Stockholders held today in Boca Raton, Florida. Approximately 74
percent of the Company's outstanding shares were voted either in person or
by proxy at the meeting, with each director receiving the support of at
least 87 percent of those shares voted. The directors have been elected to
serve a term expiring at the Company's 2007 annual meeting of stockholders.
In addition, the appointment of Ernst & Young LLP was ratified as the
Company's independent registered public accounting firm for the fiscal year
ending December 30, 2006.
About Nabi Biopharmaceuticals
Nabi Biopharmaceuticals leverages its experience and knowledge in
powering the immune system to develop and market products that fight
serious medical conditions. The company has three products on the market
today: PhosLo(R) (calcium acetate), Nabi-HB(R) [Hepatitis B Immune Globulin
(Human)], and Aloprim(TM) (allopurinol sodium) for Injection. Nabi
Biopharmaceuticals is focused on developing products that address unmet
medical needs and offer commercial opportunities in our core business
areas: Gram-positive bacterial infections, hepatitis and transplant, kidney
disease (nephrology) and nicotine addiction. For a complete list of
pipeline products, please go to: http://www.nabi.com/pipeline/index.php .
The company is headquartered in Boca Raton, Florida. For additional
information about Nabi Biopharmaceuticals, please visit our website:
http://www.nabi.com .
SOURCE Nabi Biopharmaceuticals
 back to top
Related links:
http://www.nabi.com
http://www.nabi.com/pipeline/index.php
CONTACT:
Thomas E. Rathjen, Vice President, Investor
Relations, Nabi Biopharmaceuticals, +1-561-989-5800
|
